Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Jun 30;10(6):73.
doi: 10.1038/s41408-020-0337-y.

B-cell maturation antigen expression across hematologic cancers: a systematic literature review

Affiliations
Meta-Analysis

B-cell maturation antigen expression across hematologic cancers: a systematic literature review

Ahmet Dogan et al. Blood Cancer J. .

Abstract

B-cell maturation antigen (BCMA) plays a critical role in regulating B-cell proliferation and survival. There is evidence for BCMA expression in various hematologic malignancies, suggesting that BCMA may play an important role as a biomarker or therapeutic target in these diseases. Given advances in understanding the role of BCMA in B-cell development and the promise of BCMA as a therapeutic target, a systematic review is needed to rigorously assess the evidence for BCMA expression and identify areas of consensus and future research. The objective of this review was to summarize the evidence on BCMA protein and mRNA expression across hematologic malignancies. Using a PubMed database search up to 28 August 2019, a systematic literature review of publications reporting BCMA expression in patients with hematologic malignancies was conducted. Data from published congress abstracts presented at the American Society of Clinical Oncology and the American Society of Hematology were also searched. Studies that assessed BCMA expression (protein or mRNA) in patients of any age with hematologic malignancies were included. A total of 21 studies met inclusion criteria and were included in the review. BCMA was expressed in several hematologic malignancies, including multiple myeloma (MM), chronic lymphocytic leukemia, acute B-lymphoblastic leukemia, non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma. BCMA was expressed at uniformly high levels across all 13 MM studies and at low to moderate levels in acute myeloid leukemia and acute lymphoblastic leukemia. These results suggest that BCMA is a relevant target in MM as well as in a subset of B-cell leukemia. BCMA expression in Hodgkin lymphoma and NHL varied across studies, and further research is needed to determine the utility of BCMA as an antibody target and biomarker in these diseases. Differences in sample type, timing of sample collection, and laboratory technique used may have affected the reporting of BCMA levels.

PubMed Disclaimer

Conflict of interest statement

N.T., A.F., J.F., and R.B. are employees of and own stock in Amgen, Inc, developer of 2 BiTE® immunotherapies (AMG 420 and AMG 701) and 1 ADC (AMG 224) targeting BCMA. O.L. received grants/research support from Celgene, Amgen, BMS, and Karyopharm; received grants/research support, honoraria, and other from Janssen; received grants/research support and other for Takeda; received honoraria from Celgene, Amgen, and Adaptive Biotech; and received other from Merck. A.D. received honoraria and consulting or advisory role fees from Roche, Corvus Pharmaceuticals, Physicians’ Education Resource, Seattle Genetics, Peerview Institute, Oncology Specialty Group, Pharmacyclics, Celgene, Novartis, Takeda, and EUSAPharma; and research grants from National Cancer Institute and Roche. D.S. received honoraria and consulting or advisory role fees from Celgene, Amgen, Merck, Janssen, BMS, Takeda, and Karyopharm; participated in speakers’ bureaus for Celgene, Amgen, Merck, Janssen, BMS, and Takeda; and received research funding from Celgene.

Figures

Fig. 1
Fig. 1. Identification of relevant publications.
a Animal studies, studies using non-human and/or non-hematologic cell lines, studies investigating non-hematologic conditions, review articles, comments, editorials, letters, guidelines, legal cases, debates, newspaper articles, opinions, protocols, workshops, patient education brochures, and non-English publications were excluded. b Three studies were identified from reference lists of review publications.
Fig. 2
Fig. 2. BCMA expression in normal B-cell development and in hematologic malignancies.
In the top part of the figure, normal B-cell development is shown from left to right starting from pro-B-cell to the terminally differentiated plasma cell. The presence of immunoglobulin and BCMA expression is indicated in each developmental stage. In the bottom half of the figure, the cell of origin of various mature B-cell malignancies and relative intensity of BCMA expression are shown.

Similar articles

Cited by

References

    1. Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7:1187–1199. - PMC - PubMed
    1. O’Connor BP, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 2004;199:91–98. - PMC - PubMed
    1. Laurent SA, et al. γ-secretase directly sheds the survival receptor BCMA from plasma cells. Nat. Commun. 2015;6:7333. - PMC - PubMed
    1. Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front. Immunol. 2018;9:1821. - PMC - PubMed
    1. Topp MS, et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces response in multiple myeloma. J. Clin. Oncol. 2020;38:775–783. - PubMed

Publication types

MeSH terms